SEMA4D and Rett syndrome: Both the 4-week cohort (pre-symptomatic) and 8-week (symptomatic) anti-SEMA4D antibody-treated Rett syndrome cohorts showed significant improvements in the phenotypic clinical scores relative to the isotype control antibody groups.